Publicacións en colaboración con investigadores/as de University of Szeged (81)

2024

  1. Evidence-based definition of hypoprolactinemia in European men aged 40–86 years: the European male ageing study

    Reviews in Endocrine and Metabolic Disorders

  2. Hyponatremia, hypernatremia and impairment of functional, psychological and sexual domains

    Journal of Endocrinological Investigation, Vol. 47, Núm. 4, pp. 1005-1014

  3. Insulin-like peptide 3 (INSL3) as an indicator of leydig cell insufficiency (LCI) in Middle-aged and older men with hypogonadism: reference range and threshold

    Aging Male, Vol. 27, Núm. 1

2023

  1. Does testosterone influence the association between sleep and frailty in men: results from the European Male Aging Study

    BMC Geriatrics, Vol. 23, Núm. 1

  2. Sarcopenia-defining parameters, but not sarcopenia, are associated with cognitive domains in middle-aged and older European men

    Journal of Cachexia, Sarcopenia and Muscle, Vol. 14, Núm. 3, pp. 1520-1532

2022

  1. Association of age, hormonal, and lifestyle factors with the Leydig cell biomarker INSL3 in aging men from the European Male Aging Study cohort

    Andrology, Vol. 10, Núm. 7, pp. 1328-1338

  2. Reproductive hormone levels, androgen receptor CAG repeat length and their longitudinal relationships with decline in cognitive subdomains in men: The European Male Ageing Study.

    Physiology and Behavior, Vol. 252

  3. The Leydig cell biomarker INSL3 as a predictor of age-related morbidity: Findings from the EMAS cohort

    Frontiers in Endocrinology, Vol. 13

2021

  1. Inflammatory markers are associated with quality of life, physical activity, and gait speed but not sarcopenia in aged men (40–79 years)

    Journal of Cachexia, Sarcopenia and Muscle, Vol. 12, Núm. 6, pp. 1818-1831

  2. Self-Reported Shorter Than Desired Ejaculation Latency and Related Distress—Prevalence and Clinical Correlates: Results From the European Male Ageing Study

    Journal of Sexual Medicine, Vol. 18, Núm. 5, pp. 908-919

2018

  1. Elevated luteinizing hormone despite normal testosterone levels in older men—natural history, risk factors and clinical features

    Clinical Endocrinology, Vol. 88, Núm. 3, pp. 479-490

  2. Reproductive hormone levels predict changes in frailty status in community-dwelling older men: European male ageing study prospective data

    Journal of Clinical Endocrinology and Metabolism, Vol. 103, Núm. 2, pp. 701-709

  3. Symptomatic androgen deficiency develops only when both total and free testosterone decline in obese men who may have incident biochemical secondary hypogonadism: Prospective results from the EMAS

    Clinical Endocrinology, Vol. 89, Núm. 4, pp. 459-469

2017

  1. Changes in prevalence of obesity and high waist circumference over four years across European regions: the European male ageing study (EMAS)

    Endocrine, Vol. 55, Núm. 2, pp. 456-469

  2. Evaluation of cognitive subdomains, 25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D in the European Male Ageing Study

    European Journal of Nutrition, Vol. 56, Núm. 6, pp. 2093-2103

  3. Frailty and bone health in European men

    Age and Ageing, Vol. 46, Núm. 4, pp. 635-641

  4. Glycemia but not the Metabolic Syndrome is Associated with Cognitive Decline: Findings from the European Male Ageing Study

    American Journal of Geriatric Psychiatry, Vol. 25, Núm. 6, pp. 662-671

  5. Nonandrogenic anabolic hormones predict risk of frailty: European male ageing study prospective data

    Journal of Clinical Endocrinology and Metabolism, Vol. 102, Núm. 8, pp. 2798-2806

2016

  1. Chronic widespread pain is associated with worsening frailty in European men

    Age and Ageing, Vol. 45, Núm. 2, pp. 268-274

  2. Low free testosterone is associated with hypogonadal signs and symptoms in men with normal total testosterone

    Journal of Clinical Endocrinology and Metabolism, Vol. 101, Núm. 7, pp. 2647-2657